OmniAb Inc. (OABI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at OmniAb Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.00 $ — 46% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 266.5% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.11 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.12 | – | 11 | 124.10 | -121.00 | -4 | -4 |
| 2025: Q1 | -0.17 | – | 4 | 9.30 | -438.10 | -16 | -16 |
| 2025: Q2 | -0.15 | – | 4 | -48.80 | -407.40 | -5 | -5 |
| 2025: Q3 | -0.14 | – | 2 | -46.30 | -738.10 | -10 | -10 |
| 2025: Q4 | -0.11 | – | 8 | -22.50 | -169.30 | -6 | -6 |
| 2026: Q1 | -0.06 | – | 14 | 246.70 | -53.50 | -5 | -5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
OmniAb, Inc., ein Biotechnologieunternehmen, lizenziert Discovery-Research-Technologie an Pharma- und Biotech-Unternehmen sowie akademische Einrichtungen, um die Entdeckung von Therapeutika in den USA, Europa, Japan, China und Kanada zu ermöglichen.
| Employees | 89 |
|---|---|
| Headquarters | EmeryVille, CA |
| Website | omniab.com |
| IPO Date | 2. Nov 2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Matthew W. Foehr | President, CEO & Director | 1973 |
| Kurt A. Gustafson | Executive VP of Finance & CFO | 1968 |
| Charles S. Berkman J.D. | Chief Legal Officer & Secretary | 1969 |
| Cia McCaffrey | Senior Vice President of People & Talent | – |
| Bill Harriman Ph.D. | Senior Vice President of Antibody Discovery | – |
| Christel Iffland Ph.D. | Senior Vice President of Antibody Technologies | – |
| Yasmina Noubia Abdiche Ph.D. | Senior Vice President of Exploratory Research | – |
| Bob Chen | Senior Vice President of Discovery Systems | – |
| Todd Pettingill C.F.A. | Vice President of Business Development & Strategy | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.